Key Highlights

  • OncoSil Medical Europe GmbH is a PALACROS consortium partner through the PULSE Phase II study of repeat OncoSil treatment in 120 patients across five European centres.
  • OncoSil devices are supplied in-kind with no other study-related costs, which the company estimates saves about $9 million versus a company-sponsored study.
  • The release gives no start date or results for PULSE, and the savings figure is a company estimate.

OncoSil Medical Limited (ASX:OSL), a medical device company focused on localised treatments for unresectable locally advanced pancreatic cancer (LAPC) and distal cholangiocarcinoma, announced on 13 October 2026 its participation in the official launch of the PALACROS European research programme in Amsterdam.

The PALACROS programme

PALACROS is described as a European research initiative supported by the Horizon Europe programme and the EU Mission on Cancer. It brings together hospitals, researchers, patient organisations and industry partners to investigate innovative treatment approaches and improve care pathways for LAPC, with aims including closer collaboration between specialist centres, clinical evidence generation and addressing disparities in access to advanced pancreatic cancer care across Europe. The kick-off meeting aligned consortium partners on objectives and research priorities as the programme moves into implementation.

The PULSE Phase II study

OncoSil participates through its Subsidiary OncoSil Medical Europe GmbH, in the PULSE Phase II clinical study, which will investigate repeat treatment with the OncoSil device in 120 patients across five European centres. The company does not state when enrolment will begin or when results are expected.

In-kind device Supply and cost

Under the study agreement, OncoSil will provide its devices in-kind and will incur no additional study-related costs. The company says this allows it to generate clinical data in LAPC without the site, monitoring, regulatory, data management and operational expenses typically associated with a company-sponsored trial of similar scale and duration, and estimates a cost saving of approximately $9 million against an equivalent OncoSil-sponsored study. The company would still benefit from the evidence generated, though it would not control the study.

Company focus

The release says the consortium gives OncoSil a chance to engage with leading European pancreatic cancer specialists. The announcement contains no revenue, regulatory or reimbursement information, and the PULSE results would not be expected until the study has run its course.

Company focus

OncoSil is a medical device company focused on localised treatments for unresectable locally advanced pancreatic cancer and distal cholangiocarcinoma. The announcement describes the PALACROS collaboration as aiming to improve access to multidisciplinary pancreatic cancer care and to support innovative treatment strategies across Europe.

Limits of the announcement

The release does not state the PULSE start date, recruitment timetable, endpoints or expected reporting date. The estimated $9 million saving compares an in-kind arrangement with a hypothetical company-sponsored study and is not a reduction in OncoSil's current expenditure. The company describes the in-kind structure as capital-efficient while allowing it to benefit from the clinical evidence generated.